HR+/HER2-

August 24, 2020August 24, 2020

EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation

News

The European Commission has approved Novartis‘s Piqray (alpelisib) in combination with Faslodex (fulvestrant) for the treatment of advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor-2-negative ... Read more

May 29, 2019May 29, 2019

FDA Approves Piqray-Faslodex Combo for Some Patients with Advanced Breast Cancer

News

Breast cancer patients in the U.S. who are receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-), and have mutated PIK3CA can now be treated with Novartis‘ Piqray (alpelisib) ... Read more

June 5, 2017June 7, 2017

Kisqali, Femara Combo Shows Promise in HR+/HER2- Advanced Breast Cancer Patients

News

The latest results from the Phase 3 MONALEESA-2 study showed that adding Novartis’ Kisqali (ribociclib) to ‎Femara (letrozole) for the treatment of breast cancer in certain postmenopausal women improves the time ... Read more